Article
Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases - 1 Mar 2020
Wu Yin, Fan Jiaojiao, Liao Guichan, Xia Muye, Jiang Deke, Peng Jie, Zhang Xiaoyong, Liu Hongyan
Abstract excerpt
Discontinuation of nucleos(t)ide analogue (NA) therapy in patients with chronic hepatitis B (CHB) remains a global but controversial problem. Clinical outcomes of NA cessation depend on the interplay between viral factors and host immunity. Recent studies have shown that genetic polymorphisms might influence the immune response in chronic HBV infection. A total of 33 single-nucleotide polymorphisms (SNPs) from 16...
Topics
- Adult
- Antiviral Agents
- Chemokine CXCL13
- Female
- Hepatitis B, Chronic
- Humans
- Kaplan-Meier Estimate
- Lymphocytes
- Male
- Middle Aged
- Pharmacogenomic Variants
- Polymorphism, Single Nucleotide